ArticleACS omega2026
Poly(2-oxazoline)-Based Lipid Nanocapsules Containing Free Hydroxyl Group as Promising Alternative to Conventional PEG-Lipid Nanocapsules.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipid nanocapsules (LNCs) are attractive nanocarriers owing to their high colloidal stability and cytocompatibility. However, their current formulation relies on the poly-(ethylene glycol) (PEG)-based surfactant Kolliphor HS 15, whose clinical use is increasingly compromised by the emergence of anti-PEG antibodies leading to rapid clearance of PEGylated treatments. Poly-(2-oxazoline)-s (POx) share various similarities with PEG such as stealth properties, neutrality, high water solubility, cytocompatibility with enhanced chemical tunability and lower immunogenicity. Here, we report the synthesis of two POx-based surfactants using a copper-free azide-alkyne cycloaddition, enabling their efficient conjugation with hydrophobic chains under conditions compatible with biological applications. Incorporation of these surfactants into LNCs provided nanoparticles with hydrodynamic diameters of ∼63-74 nm and concentrations around 10
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.